CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Kausik Ray, MBChB, MD, MPhil
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%
Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Amy Mottl, MD, MPH
Muthiah Vaduganathan, MD, MPH
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Prof. Christoph Wanner
Bridging ASCVD Care Between Academic and Rural Settings
Rishi Wadhera, MD, MPP, Mphil
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.